TruScreen (NZX:TRU)
ASX announcement history & article coverage
Transparent by design.
Announcments by TruScreen (NZX:TRU) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
SPH Notice - Peter Hanbury Masfen, Joanna Alison Masfen, Anatole Guy Hanbury Masfen, and Raphael William Wai–ming Yan
TRU – Waivers from NZX Listing Rules 4.19.1 and 7.8.5(b)
Notice of Special Meeting + Proxy Form
Corporate Action Notice
Truscreen completes 17.4% Renounceable Rights Issue raising capital through new share issuance
Change in Substantial Shareholding Notice
Initial Substantial Shareholder Notice
Truscreen Annual Report 31 March 2026
TruScreen reports FY2026 net loss with going concern uncertainty highlighted by auditor
TruScreen Completes Rights Issue and Shortfall Bookbuild
TruScreen completes oversubscribed NZ$2.9m rights issue raising over NZ$4m total capital
Rights Issue Offer to Close 17 June 2026
Initial Director Disclosure Notice Reece O'Connell
Director Resignation/Retirement
Capital Change Notice
Management Update
TruScreen Prelimnary Final FY2026 Results Commentary
TruScreen posts 42% sales growth in FY2026, expands global footprint, and advances cervical cancer screening programs
TruScreen Results FY2026 Summary
Truscreen reports 42% revenue growth but sustained net loss for FY2026
TruScreen FY2026 Prelimnary Final Results
Truscreen reports NZD 2.25m loss for FY26 with revenue growth and capital raise amid going concern risks
TruScreen FY2026 Prelimnary Final Results Presentation
TruScreen reports 42% sales growth in FY2026, expands global footprint and advances regulatory approvals with strong FY2027 outlook
TruScreen Appoints Uzbekistan Distributor and Commences Pilot Clinical Study
TruScreen Group Limited (“TRU”) – Trading to resume
TruScreen Completes Oversubscribed Placement
TruScreen completes oversubscribed NZ$1.82m placement with options and announces upcoming rights issue
Cleansing Notice
TruScreen Options Extension Prospectus
TruScreen extends option expiry to July 2027 with nil-cost issue to Australian holders
TruScreen Share Rights Issue Offer Document
TruScreen launches NZ$1.94M rights issue to fund global cervical cancer screening expansion
Corporate Action Notice
TruScreen announces rights issue, placement, and bonus options to raise up to NZ$1 million
TruScreen Investor Presentation
TruScreen reports strong FY26 growth, expands global cervical cancer screening reach with AI technology and strategic partnerships
TruScreen Capital Raise Announcement
TruScreen launches NZ$2.9 million capital raise to fuel global expansion and extends option expiry
TruScreen Group Limited (“TRU”) – Trading Halt of Securities
TruScreen Group Limited Trading Halt Request
Change of Auditors
Truscreen Partners with LSUTH on Gates Foundation Grant Application
FY 31 March 2026 Revenue and Results Guidance Achieved
TruScreen meets FY2026 revenue guidance with 41% sales growth; invests in market expansion and pursues major UNITAID funding
TruScreen Submits Three Proposals to UNITAID's Global Cervical Cancer Elimination Call